Ginkgo Bioworks Holdings (DNA) Accumulated Expenses (2020 - 2025)

Ginkgo Bioworks Holdings filings provide 6 years of Accumulated Expenses readings, the most recent being $66.5 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 1.64% to $66.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $66.5 million, a 1.64% increase, with the full-year FY2025 number at $66.5 million, up 1.64% from a year prior.
  • Accumulated Expenses hit $66.5 million in Q4 2025 for Ginkgo Bioworks Holdings, down from $79.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $122.6 million in Q1 2023 to a low of $53.6 million in Q3 2021.
  • Median Accumulated Expenses over the past 5 years was $84.0 million (2022), compared with a mean of $88.4 million.
  • Biggest five-year swings in Accumulated Expenses: surged 205.96% in 2021 and later crashed 51.13% in 2025.
  • Ginkgo Bioworks Holdings' Accumulated Expenses stood at $93.3 million in 2021, then increased by 22.89% to $114.7 million in 2022, then decreased by 4.05% to $110.1 million in 2023, then crashed by 40.58% to $65.4 million in 2024, then grew by 1.64% to $66.5 million in 2025.
  • The last three reported values for Accumulated Expenses were $66.5 million (Q4 2025), $79.3 million (Q3 2025), and $57.2 million (Q2 2025) per Business Quant data.